Capricor Therapeutics Reports Third Quarter 2015 Business & Financial Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Capricor Therapeutics (CAPR) Tops Q3 EPS by 8c
November 12, 2015 4:25 PM ESTCapricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.18), $0.08 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $0 versus the consensus estimate of $1.1 million.
For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.
... More